Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis

References

• Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75:284–291.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113:1649–1659.
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896–904.
   PubMed Web of Science ®Google Scholar
• Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175–1183.
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Kachru N, Zamorano MA, et al. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Medicine. 2020;99:e23506.
   PubMed Web of Science ®Google Scholar
• Canbay A, Kachru N, Haas JS, et al. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Ann Transl Med. 2021;9:615.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Kachru N, Martinez DJ, et al. Real-world comorbidity burden, health care utilization, and costs of nonalcoholic steatohepatitis patients with advanced liver diseases. J Clin Gastroenterol. 2021;55:891–902.
   PubMed Web of Science ®Google Scholar
• Gordon SC, Fraysse J, Li S, et al. Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis Medicare patients. Am J Gastroenterol. 2020;115:562–574.
   PubMed Web of Science ®Google Scholar
• Gordon SC, Kachru N, Parker E, et al. Health care use and costs among patients with nonalcoholic steatohepatitis with advanced fibrosis using the fibrosis-4 score. Hepatol Commun. 2020;4:998–1011.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Tampi R, Priyadarshini M, et al. Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States. Hepatology. 2019;69:564–572.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–1565.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Hayward KL, Johnson AL, Horsfall LU, et al. Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. BMJ Open Gastroenterol. 2021;8:e000572.
   PubMed Web of Science ®Google Scholar
• Corey KE, Kartoun U, Zheng H, et al. Development and validation of an algorithm to identify nonalcoholic fatty liver disease in the electronic medical record. Dig Dis Sci. 2016;61:913–919.
   PubMed Web of Science ®Google Scholar
• Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–1112.
   PubMed Web of Science ®Google Scholar
• Johnson AL, Hayward KL, Patel P, et al. Predicting liver-related outcomes in people with nonalcoholic fatty liver disease: the prognostic value of noninvasive fibrosis tests. Hepatol Commun. 2022;6:728–739.
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305–315.
   PubMed Web of Science ®Google Scholar
• Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am J Med Qual. 2006;21:269–275.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12:e1001885.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25:3–9.
   PubMed Web of Science ®Google Scholar
• Hagström H, Adams LA, Allen AM, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74:474–482.
   PubMed Web of Science ®Google Scholar
• Qayed E, Migdal AL, Jagannathan R, et al. Characteristics and outcomes of black and white patients hospitalized with nonalcoholic steatohepatitis: a nationwide analysis. J Clin Gastroenterol. 2022. DOI:10.1097/MCG.0000000000001698
   PubMed Web of Science ®Google Scholar
• Pemmasani G, Yandrapalli S, Aronow W. Sex differences in cardiovascular diseases and associated risk factors in non-alcoholic steatohepatitis. Am J Cardiovasc Dis. 2020;10:362–366.
   PubMed Web of Science ®Google Scholar
• Schattenberg J, Alkhouri N, Taub R, et al. OS101 - utility of FIB-4 thresholds to identify patients with at-risk F2-F3 NASH based on screening data from a 2000 patient biopsy confirmed cohort of resmetirom phase 3 clinical trial, MAESTRO-NASH. J Hepatol. 2022;77:s75.
   Web of Science ®Google Scholar
• Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology. 2019;70:1521–1530.
   PubMed Web of Science ®Google Scholar
• Loomba R, Harrison SA, Taub R, et al. Utility of FIB-4, MRE, MRI-PDFF and fibroscan to identify patients with at-risk f2-f3 nash based on screening data from a 2000 patient biopsy confirmed cohort of resmetirom phase 3 clinical trial, MAESTRO-NASH. Presented at: the AASLD; 2022 Nov 6; Boston, MA. Hepatology [Internet]. 2022 [cited 2023 Feb 8]. Available from: https://www.aasld.org/the-liver-meeting/utility-fib-4-mre-mri-pdff-and-fibroscan-identify-patients-risk-f2-f3-nash-based
   Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Glasheen WP, Renda A, Dong Y. Diabetes complications severity index (DCSI)—update and ICD-10 translation. J Diabetes Complications. 2017;31:1007–1013.
   PubMed Web of Science ®Google Scholar
• Goff DC, Lloyd-Jones Donald M, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014;63:2935–2959.
   PubMed Web of Science ®Google Scholar
• Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528–562.
   PubMed Web of Science ®Google Scholar
• O’Hara J, Finnegan A, Dhillon H, et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep. 2020;2:100142.
   PubMedGoogle Scholar
• Geier A, Rinella ME, Balp M-M, et al. Real-world burden of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021;19:1020.e7–1029.e7.
   Web of Science ®Google Scholar
• Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. DOI:10.1097/HEP.0000000000000323
   PubMedGoogle Scholar
• Eskridge W, Vierling JM, Gosbee W, et al. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a population-based risk factor assessment using vibration controlled transient elastography (VCTE). PLoS One. 2021;16:e0260320.
   PubMed Web of Science ®Google Scholar